EUVIMEDEUVIMED entdecken
Kommentar

In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding

Manasi Tannu, L Kristin Newby

Annals of Internal Medicine · 2023

DOI: 10.7326/j23-0090 ↗

Kurz gefasst

Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Manasi Tannu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Duke University School of Medicine, Durham, North Carolina, USA (M.T., L.K.N.). Hauptthemen laut MEDLINE: Aspirin, Percutaneous Coronary Intervention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SOURCE CITATION: Gragnano F, Cao D, Pirondini L, et al; PANTHER Collaboration. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2023;82:89-105. 37407118.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinPercutaneous Coronary InterventionHumansPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsHemorrhageTreatment OutcomeDrug Therapy, Combination

Substanzen

AspirinPlatelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonists

Autor:innen und Institutionen

  • Duke University School of Medicine, Durham, North Carolina, USA (M.T., L.K.N.).

Zitieren

APA

Tannu, M., & Newby, L. K. (2023). In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding. Annals of Internal Medicine. https://doi.org/10.7326/j23-0090

Vancouver

Tannu M, Newby LK. In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding. Annals of Internal Medicine. 2023. doi:10.7326/j23-0090

BibTeX
@article{Tannu2023,
  author = {Tannu, Manasi and Newby, L Kristin},
  title = {In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding},
  journal = {Annals of Internal Medicine},
  year = {2023},
  doi = {10.7326/j23-0090}
}
Kostenlos starten →